Program
SHR-3167
A development code. Also written as “SHR-3167 Injection” and “SHR-3167 injection;glargine insulin”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 97 open or running | phase 3since Oct 28, 2026 | Aug 2, 2023 | Dec 2026phase 2 · NCT07472725 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-3167
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 2, 2023First study: phase 1 study in T2DMFirst studyNCT05996380 · 52 planned · China
- Nov 12, 2024Phase 2 study in Diabetes Mellitus, Type 2NCT06688123 · 275 enrolled · China
- Jun 5, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT07018453 · 173 enrolled · China
- Jun 16, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07032688 · 55 planned · China
- Mar 11, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07472725 · 102 enrolled · China
- Mar 18, 2026Phase 1 study in Diabetes MellitusNCT07489482 · 60 planned · China
- May 8, 2026Phase 1 study in Healthy SubjectsNCT07588906 · 24 enrolled · China
- Oct 28, 20262 phase 3 studies in Diabetes Mellitus, Type 2Phase 3 reachedNCT07913061, NCT07920939
Ahead
- Dec 2026Primary completion: phase 1 study in Diabetes MellitusNCT07489482
- Dec 2026Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07472725
- Mar 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07032688
- Oct 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07920939
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07920939Diabetes Mellitus, Type 2 · China | 3 | Not yet recruiting | Oct 2027 | 450 |
| NCT07913061Diabetes Mellitus, Type 2 · China | 3 | Not yet recruiting | Jan 2028 | 680 |
| NCT07588906Healthy Subjects · China | 1 | Completed | Jul 12, 2024 | 24 |
| NCT07489482Diabetes Mellitus · China | 1 | Recruiting | Dec 2026 | 60 |
| NCT07472725Diabetes Mellitus, Type 2 · China | 2 | Active, not recruiting | Dec 2026 | 102 |
| NCT07032688Diabetes Mellitus, Type 2 · China | 1 | Recruiting | Mar 2027 | 55 |
| NCT07018453Diabetes Mellitus, Type 2 · China | 2 | Active, not recruiting | Feb 2026 | 173 |
| NCT06688123Diabetes Mellitus, Type 2 · China | 2 | Completed | Apr 22, 2026 | 275 |
| NCT05996380T2DM · China | 1 | Recruiting | Jan 25, 2024 | 52 |
How it is read
Names in the registry
- “SHR-3167”, 5 entries
- “SHR-3167 Injection”, 4 entries
- “SHR-3167 injection;glargine insulin”, 1 entry
Codes read as this program: SHR3167.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 6 studies
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.